Evidence map›Paper›PMID 39132746›Full record

Trial reportJournal of comparative effectiveness research2024

A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.

Jeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, Maryaline Catillon, Chunyi Xu, Alice Qu, Francesca Lee, Ann Childress

Abstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jeff ScheinOtsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ 08540, USA.
Martin CloutierAnalysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada.ORCID 0000-0002-4867-4739
Marjolaine Gauthier-LoiselleAnalysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada.ORCID 0000-0002-9439-595X
Maryaline CatillonAnalysis Group, Inc., 151 West 42nd Street, 23rd Floor, New York, NY 10036, USA.ORCID 0000-0002-1360-8133
Chunyi XuAnalysis Group, Inc., 151 West 42nd Street, 23rd Floor, New York, NY 10036, USA.
Alice QuAnalysis Group, Inc., 151 West 42nd Street, 23rd Floor, New York, NY 10036, USA.
Francesca LeeAnalysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada.
Ann ChildressCenter for Psychiatry & Behavioral Medicine, 7351 Prairie Falcon Rd STE 160, Las Vegas, NV 89128, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Atomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsLisdexamfetamine DimesylateMethylphenidateAdrenergic Uptake InhibitorsAdultFemaleHumansMaleMiddle AgedTreatment OutcomeYoung AdultAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideCentral Nervous System StimulantsLisdexamfetamine DimesylateMethylphenidateadverse eventsattention-deficit/hyperactivity disordercentanafadineclinical trialscomparative effectiveness researchefficacyindirect comparisonpropensity scoretreatment outcome

Identifiers

PMID39132746
PMCPMC11363209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.